Lucid Diagnostics (LUCD), a unit of PAVmed (PAVM), said Tuesday it agreed to sell 13.9 million shares at $1.10 each in a registered direct offering.
Gross proceeds are anticipated to total $15.3 million and the transaction is expected to close on Wednesday, the company said.
Lucid Diagnostics said net proceeds will be used for working capital and general corporate purposes.
The company's shares were down nearly 18% in recent Tuesday premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。